Table Info

Table 1.

Polarization and identification of macrophage, neutrophil, and MDSC subtypes

Cell type	Subtypes	Polarizing cytokines	Differentiating markers
Macrophages	M1	IFN-γ, TNF-α	CD80⁺, CD86⁺, iNOS⁺
Macrophages	M2	M-CSF, IL-4, IL-6, IL-10, IL-13, IL-34	CD163⁺, CD206⁺, Arg1⁺
Neutrophils	N1	IFN-β	Expression of: CXCL9, CXCL10, TNF-α, IL-12, GM-CSF, iNOS
Neutrophils	N2	TGF-β, G-CSF	Expression of: VEGF, MMP9, Arg1
MDSCs	PMN-MDSCs	CXCL1, CXCL2, CXCL5	Human: CD11b⁺, CD14^–, CD15⁺/CD66b⁺ Mouse: CD11b, Ly6C^low, Ly6G⁺
MDSCs	M-MDSCs	CCL-2	Human: CD11b⁺, CD14^–, CD15^–/CD66b^– Mouse: CD11b⁺, Ly6C^high, Ly6G^–

Declarations

Author contributions

DDDO and DM: Conceptualization, Writing—original draft, Writing—review & editing. GNG: Funding acquisition, Supervision, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was supported by the Kansas Institute for Precision Medicine NIGMSCOBRE grant [P20GM130423]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. [DOI] [PubMed]

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. [DOI] [PubMed]

Pisani P, Airoldi M, Allais A, Aluffi Valletti P, Battista M, Benazzo M, et al. Metastatic disease in head & neck oncology. Acta Otorhinolaryngol Ital. 2020;40:S1–86. [DOI] [PubMed] [PMC]

Welch DR, Hurst DR. Defining the hallmarks of metastasis. Cancer Res. 2019;79:3011–27. [DOI] [PubMed] [PMC]

Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22:6995. [DOI] [PubMed] [PMC]

Takiguchi H, Yang CX, Yang CWT, Sahin B, Whalen BA, Milne S, et al. Macrophages with reduced expressions of classical M1 and M2 surface markers in human bronchoalveolar lavage fluid exhibit pro-inflammatory gene signatures. Sci Rep. 2021;11:8282. [DOI] [PubMed] [PMC]

Kumar AT, Knops A, Swendseid B, Martinez-Outschoom U, Harshyne L, Philp N, et al. Prognostic significance of tumor-associated macrophage content in head and neck squamous cell carcinoma: a meta-analysis. Front Oncol. 2019;9:656. [DOI] [PubMed] [PMC]

Bisheshar SK, van der Kamp MF, de Ruiter EJ, Ruiter LN, van der Vegt B, Breimer GE, et al. The prognostic role of tumor associated macrophages in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. Oral Oncol. 2022;135:106227. [DOI] [PubMed]

Kondoh N, Mizuno-Kamiya M. The role of immune modulatory cytokines in the tumor microenvironments of head and neck squamous cell carcinomas. Cancers (Basel). 2022;14:2884. [DOI] [PubMed] [PMC]

10.

Jeannin P, Paolini L, Adam C, Delneste Y. The roles of CSFs on the functional polarization of tumor-associated macrophages. FEBS J. 2018;285:680–99. [DOI] [PubMed]

11.

Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18:349–55. [DOI] [PubMed]

12.

Chen R, Lu X, Li Z, Sun Y, He Z, Li X. Dihydroartemisinin prevents progression and metastasis of head and neck squamous cell carcinoma by inhibiting polarization of macrophages in tumor microenvironment. Onco Targets Ther. 2020;13:3375–87. [DOI] [PubMed] [PMC]

13.

Baumeister P, Zhou J, Canis M, Gires O. Epithelial-to-mesenchymal transition-derived heterogeneity in head and neck squamous cell carcinomas. Cancers (Basel). 2021;13:5355. [DOI] [PubMed] [PMC]

14.

Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell. 2017;171:1611–24.e24. [DOI] [PubMed] [PMC]

15.

Hu Y, He MY, Zhu LF, Yang CC, Zhou ML, Wang Q, et al. Tumor-associated macrophages correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma. J Exp Clin Cancer Res. 2016;35:12. [DOI] [PubMed] [PMC]

16.

You Y, Tian Z, Du Z, Wu K, Xu G, Dai M, et al. M1-like tumor-associated macrophages cascade a mesenchymal/stem-like phenotype of oral squamous cell carcinoma via the IL6/Stat3/THBS1 feedback loop. J Exp Clin Cancer Res. 2022;41:10. [DOI] [PubMed] [PMC]

17.

Yamagata Y, Tomioka H, Sakamoto K, Sato K, Harada H, Ikeda T, et al. CD163-positive macrophages within the tumor stroma are associated with lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma. J Oral Maxillofac Surg. 2017;75:2144–53. [DOI] [PubMed]

18.

MumprechtV, Detmar M. Lymphangiogenesis and cancer metastasis. J Cell Mol Med. 2009;13:1405–16. [DOI] [PubMed] [PMC]

19.

Garley M, Jabłońska E. Heterogeneity among neutrophils. Arch Immunol Ther Exp (Warsz). 2018;66:21–30. [DOI] [PubMed] [PMC]

20.

Kim DY, Kim IS, Park SG, Kim H, Choi YJ, Seol YM. Prognostic value of posttreatment neutrophil–lymphocyte ratio in head and neck squamous cell carcinoma treated by chemoradiotherapy. Auris Nasus Larynx. 2017;44:199–204. [DOI] [PubMed]

21.

Sumner WA, Stokes WA, Oweida A, Berggren KL, McDermott JD, Raben D, et al. Survival impact of pre-treatment neutrophils on oropharyngeal and laryngeal cancer patients undergoing definitive radiotherapy. J Transl Med. 2017;15:168. [DOI] [PubMed] [PMC]

22.

Trellakis S, Bruderek K, Dumitru CA, Gholaman H, Gu X, Bankfalvi A, et al. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int J Cancer. 2011;129:2183–93. [DOI] [PubMed]

23.

Wang N, Feng Y, Wang Q, Liu S, Xiang L, Sun M, et al. Neutrophils infiltration in the tongue squamous cell carcinoma and its correlation with CEACAM1 expression on tumor cells. PLoS One. 2014;9:e89991. [DOI] [PubMed] [PMC]

24.

Bowen RC, Little NAB, Harmer JR, Ma J, Mirabelli LG, Roller KD, et al. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget. 2017;8:32171–89. [DOI] [PubMed] [PMC]

25.

Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep. 2019;9:19673. [DOI] [PubMed] [PMC]

26.

Meunier S, Frontczak A, Balssa L, Blanc J, Benhmida S, Pernot M, et al. Elevated baseline neutrophil count correlates with worse outcomes in patients with muscle-invasive bladder cancer treated with chemoradiation. Cancers. 2023;15:1886. [DOI] [PubMed] [PMC]

27.

Tolle F, Umansky V, Utikal J, Kreis S, Bréchard S. Neutrophils in tumorigenesis: missing targets for successful next generation cancer therapies? Int J Mol Sci. 2021;22:6744. [DOI] [PubMed] [PMC]

28.

Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell. 2009;16:183–94. [DOI] [PubMed] [PMC]

29.

Andzinski L, Kasnitz N, Stahnke S, Wu CF, Gereke M, von Köckritz-Blickwede M, et al. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int J Cancer. 2016;138:1982–93. [DOI] [PubMed]

30.

Casbon AJ, Reynaud D, Park C, Khuc E, Gan DD, Schepers K, et al. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc Natl Acad Sci U S A. 2015;112:E566–75. [DOI] [PubMed] [PMC]

31.

Glogauer JE, Sun CX, Bradley G, Magalhaes MA. Neutrophils increase oral squamous cell carcinoma invasion through an invadopodia-dependent pathway. Cancer Immunol Res. 2015;3:1218–26. [DOI] [PubMed]

32.

Hu X, Xiang F, Feng Y, Gao F, Ge S, Wang C, et al. Neutrophils promote tumor progression in oral squamous cell carcinoma by regulating EMT and JAK2/STAT3 signaling through chemerin. Front Oncol. 2022;12:812044. [DOI] [PubMed] [PMC]

33.

Gordon-Weeks AN, Lim SY, Yuzhalin AE, Jones K, Markelc B, Kim KJ, et al. Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2–dependent angiogenesis in mice. Hepatology. 2017;65:1920–35. [DOI] [PubMed]

34.

Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A. 2006;103:12493–98. [DOI] [PubMed] [PMC]

35.

Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407–24. [DOI] [PubMed]

36.

Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013;123:3446–58. [DOI] [PubMed] [PMC]

37.

Park J, Wysocki RW, Amoozgar Z, Maiorino L, Fein MR, Jorns J, et al. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci Transl Med. 2016;8:361ra138. [DOI] [PubMed] [PMC]

38.

Yang L, Liu L, Zhang R, Hong J, Wang Y, Wang J, et al. IL-8 mediates a positive loop connecting increased neutrophil extracellular traps (NETs) and colorectal cancer liver metastasis. J Cancer. 2020;11:4384–96. [DOI] [PubMed] [PMC]

39.

Decker AS, Pylaeva E, Brenzel A, Spyra I, Droege F, Hussain T, et al. Prognostic role of blood NETosis in the progression of head and neck cancer. Cells. 2019;8:946. [DOI] [PubMed] [PMC]

40.

Chen N, He D, Cui J. A neutrophil extracellular traps signature predicts the clinical outcomes and immunotherapy response in head and neck squamous cell carcinoma. Front Mol Biosci. 2022;9:833771. [DOI] [PubMed] [PMC]

41.

Condamine T, Ramachandran I, Youn JI, Gabrilovich DI. Regulation of tumor metastasis by myeloid-derived suppressor cells. Ann Rev Med. 2015;66:97–110. [DOI] [PubMed] [PMC]

42.

Huang B, Lei Z, Zhao J, Gong W, Liu J, Chen Z, et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007;252:86–92. [DOI] [PubMed]

43.

Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, et al. Monocytic CCR2⁺ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 2012;72:876–86. [DOI] [PubMed] [PMC]

44.

Lim HX, Kim TS, Poh CL. Understanding the differentiation, expansion, recruitment and suppressive activities of myeloid-derived suppressor cells in cancers. Int J Mol Sci. 2020;21:3599. [DOI] [PubMed] [PMC]

45.

Pang X, Fan HY, Tang YL, Wang SS, Cao MX, Wang HF, et al. Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma. PLoS One. 2020;15:e0229089. [DOI] [PubMed] [PMC]

46.

Sceneay J, Chow MT, Chen A, Halse HM, Wong CS, Andrews DM, et al. Primary tumor hypoxia recruits CD11b⁺/Ly6C^med/Ly6G⁺ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 2012;72:3906–11. [DOI] [PubMed]

47.

Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, et al. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 2012;72:1384–94. [DOI] [PubMed] [PMC]

48.

Shi H, Zhang J, Han X, Li H, Xie M, Sun Y, et al. Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1β-mediated increase in e-selectin expression. Int J Cancer. 2017;140:1370–83. [DOI] [PubMed]

49.

MusumeciA, Lutz K, Winheim E, Krug AB. What makes a PDC: recent advances in understanding plasmacytoid DC development and heterogeneity. Front Immunol. 2019;10:1222. [DOI] [PubMed] [PMC]

50.

O’Donnell RK, Mick R, Feldman M, Hino S, Wang Y, Brose MS, et al. Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response. Cancer Lett. 2007;255:145–52. [DOI] [PubMed] [PMC]

51.

Kuhn S, Yang J, Ronchese F. Monocyte-derived dendritic cells are essential for CD8⁺ T cell activation and antitumor responses after local immunotherapy. Front Immunol. 2015;6:584. [DOI] [PubMed] [PMC]

52.

Tiberio L, Del Prete A, Schioppa T, Sozio F, Bosisio D, Sozzani S. Chemokine and chemotactic signals in dendritic cell migration. Cell Mol Immunol. 2018;15:346–52. [DOI] [PubMed] [PMC]

53.

Waskow C, Liu K, Darrasse-Jèze G, Guermonprez P, Ginhoux F, Merad M, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol. 2008;9:676–83. [DOI] [PubMed] [PMC]

54.

Veglia F, Gabrilovich DI. Dendritic cells in cancer: the role revisited. Curr Opin Immunol. 2017;45:43–51. [DOI] [PubMed] [PMC]

55.

Bruchhage KL, Heinrichs S, Wollenberg B, Pries R. IL-10 in the microenvironment of HNSCC inhibits the CpG ODN-induced IFN-α secretion of pDCs. Oncol Lett. 2018;15:3985–90. [DOI] [PubMed] [PMC]

56.

Han N, Zhang Z, Liu S, Ow A, Ruan M, Yang W, et al. Increased tumor-infiltrating plasmacytoid dendritic cells predicts poor prognosis in oral squamous cell carcinoma. Arch Oral Biol. 2017;78:129–34. [DOI] [PubMed]

57.

Han N, Li X, Wang Y, Wang L, Zhang C, Zhang Z, et al. Increased tumor-infiltrating plasmacytoid dendritic cells promote cancer cell proliferation and invasion via TNF-α/NF-κB/CXCR-4 pathway in oral squamous cell carcinoma. J Cancer. 2021;12:3045–56. [DOI] [PubMed] [PMC]

58.

Alsahafi E, Begg K, Amelio I, Raulf N, Lucarelli P, Sauter T, et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis. 2019;10:540. [DOI] [PubMed] [PMC]

59.

Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169:5538–45. [DOI] [PubMed]

60.

Yajuk O, Baron M, Toker S, Zelter T, Fainsod-Levi T, Granot Z. The PD-L1/PD-1 axis blocks neutrophil cytotoxicity in cancer. Cells. 2021;10:1510. [DOI] [PubMed] [PMC]

61.

Strauss L, Mahmoud MAA, Weaver JD, Tijaro-Ovalle NM, Christofides A, Wang Q, et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci Immunol. 2020;5:eaay1863. [DOI] [PubMed] [PMC]

62.

Klement JD, Redd PS, Lu C, Merting AD, Poschel DB, Yang D, et al. Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment. Cancer Cell. 2023;41:620–36.e9. [DOI] [PubMed]

63.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67. [DOI] [PubMed] [PMC]

64.

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet. 2019;393:156–67. [DOI] [PubMed]

65.

Moreira D, Sampath S, Won H, White SV, Su YL, Alcantara M, et al. Myeloid cell–targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell–mediated immunity. J Clin Invest. 2021;131:e137001. [DOI] [PubMed] [PMC]

66.

Karapetyan L, Luke JJ, Davar D. Toll-like receptor 9 agonists in cancer. Onco Targets Ther. 2020;13:10039–60. [DOI] [PubMed] [PMC]

67.

Sampath S, Won H, Massarelli E, Li M, Frankel P, Vora N, et al. Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients. Oncotarget. 2018;9:11279–90. [DOI] [PubMed] [PMC]

68.

Califano JA, Khan Z, Noonan KA, Rudraraju L, Zhang Z, Wang H, et al. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21:30–38. [DOI] [PubMed] [PMC]

69.

Luginbuhl AJ, Johnson JM, Harshyne LA, Linnenbach AJ, Shukla SK, Alnemri A, et al. Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma. Clin Cancer Res. 2022;28:915–27. [DOI] [PubMed] [PMC]